Relmada Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Blue Bell PA* United States (2004)

Organization Overview

First Clinical Trial
2014
NCT03637361
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Relmada Therapeutics | Relmada Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Relmada Therapeutics, Inc. (1) Acquired (2)

autologous cd34+ cells (1 trial)

dextromethadone (9 trials)

mdr-101 (1 trial)

Drugs in Phase 2 Trials (1)

Key: Relmada Therapeutics, Inc. (0) Acquired (1)

mdr-103 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Depressive Disorder, Treatment-Resistant (Phase 2)

Disease (Phase 2)

Neuralgia (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 4